Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

AZN AstraZeneca PLC

78,765

-0,275 (-0,35%)

Zuletzt aktualisiert: 18:01:56

Verzögert um 15 Minuten

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Aug 2024 bis Sep 2024

Click Here for more AstraZeneca Charts.

AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Sep 2023 bis Sep 2024

Click Here for more AstraZeneca Charts.

News AstraZeneca PLC

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
Dienstag 17 September 2024 (54 Minuten vor) • GlobeNewswire Inc.

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
Montag 16 September 2024 (1 Tag vor) • Business Wire

IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
Sonntag 15 September 2024 (2 Tage vor) • Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
Freitag 13 September 2024 (4 Tage vor) • Business Wire

SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing
Dienstag 10 September 2024 (1 Woche vor) • PR Newswire (US)

SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing
Dienstag 10 September 2024 (1 Woche vor) • PR Newswire (US)

Apple Loses EU Dispute; Google’s $2.7 Billion Fine Upheld; Oracle Shares Surge 9%
Dienstag 10 September 2024 (1 Woche vor) • IH Market News

Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
Montag 9 September 2024 (1 Woche vor) • Business Wire

Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
Sonntag 8 September 2024 (1 Woche vor) • Business Wire

Qualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual Listing
Donnerstag 5 September 2024 (2 Wochen vor) • IH Market News

AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024
Dienstag 3 September 2024 (2 Wochen vor) • Business Wire

Cruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1%
Freitag 23 August 2024 (4 Wochen vor) • IH Market News

Weitere AstraZeneca PLC News-Artikel

Deutsche Telekom (QX)

Deutsche Lufthansa

BNP Paribas (QX)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen